ArticlePloS one2014
Lantibiotic immunity: inhibition of nisin mediated pore formation by NisI.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Enhanced antibacterial and anti-biofilm activity of PEGylated niosomes co-loaded with nisin and ZnO nanoparticles against VRSA and ceftazidime-resistant Pseudomonas aeruginosa.Archives of microbiology · 2026Article
- The DdD protein confers intracellular and extracellular immunity to the leaderless bacteriocin enterocin DD14.PNAS nexus · 2026Article
- A comparative framework of natural nisin variants: linking genetic basis to future bioengineering applications.Microbial cell factories · 2026Review
- Modulating gut microbial biofilms for intestinal barrier repair: opportunities in nutritional intervention.Frontiers in nutrition · 2026Review
- Enhancing bovicin HC5 production in Streptococcus equinus HC5 through adaptive laboratory evolution under thermal stress.Applied microbiology and biotechnology · 2025Article
- A Function of Amyloid-β in Mediating Activity-Dependent Axon/Synapse Competition May Unify Its Roles in Brain Physiology and Pathology.Journal of Alzheimer's disease : JAD · 2023Review
- New insights into the resistance mechanism for the BceAB-type transporter SaNsrFP.Scientific reports · 2022Article
- In Silico Prediction and Analysis of Unusual Lantibiotic Resistance Operons in the GenusMicroorganisms · 2021Article
- Gene-Trait Matching and Prevalence of Nisin Tolerance Systems inFrontiers in bioengineering and biotechnology · 2021Article
- Silver (I)Pharmaceutics · 2020Article
- NisI Maturation and Its Influence on Nisin Resistance in Lactococcus lactis.Applied and environmental microbiology · 2020Article
- Impact of the nisin modification machinery on the transport kinetics of NisT.Scientific reports · 2020Article
- Kunkecin A, a New Nisin Variant Bacteriocin Produced by the Fructophilic Lactic Acid Bacterium,Frontiers in microbiology · 2020Article
- Insights in the Antimicrobial Potential of the Natural Nisin Variant Nisin H.Frontiers in microbiology · 2020Article
- Nisin Production by Enterococcus hirae DF105Mi Isolated from Brazilian Goat Milk.Probiotics and antimicrobial proteins · 2019Article
- LanI-Mediated Lantibiotic Immunity in Bacillus subtilis: Functional Analysis.Applied and environmental microbiology · 2019Article
- Systematic characterization of position one variants within the lantibiotic nisin.Scientific reports · 2019Article
- Contribution of YthA, a PspC Family Transcriptional Regulator of Lactococcus lactis F44 Acid Tolerance and Nisin Yield: a Transcriptomic Approach.Applied and environmental microbiology · 2018Article
- Crystal Structure of NisI in a Lipid-Free Form, the Nisin Immunity Protein, from Lactococcus lactis.Antimicrobial agents and chemotherapy · 2018Article
- New bacitracin-resistant nisin-producing strain ofAIMS microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nisin, a 3.4 kDa antimicrobial peptide produced by some Lactococcus lactis strains is the most prominent member of the lantibiotic family. Nisin can inhibit cell growth and penetrates the target Gram-positive bacterial membrane by binding to Lipid II, an essential cell wall synthesis precursor. The assembled nisin-Lipid II complex forms pores in the target membrane. To gain immunity against its own-produced nisin, Lactococcus lactis is expressing two immunity protein systems, NisI and NisFEG. Here, we show that the NisI expressing strain displays an IC50 of 73 ± 10 nM, an 8-10-fold increase when compared to the non-expressing sensitive strain. When the nisin concentration is raised above 70 nM, the cells expressing full-length NisI stop growing rather than being killed. NisI is inhibiting nisin mediated pore formation, even at nisin concentrations up to 1 µM. This effect is induced by the C-terminus of NisI that protects Lipid II. Its deletion showed pore formation again. The expression of NisI in combination with externally added nisin mediates an elongation of the chain length of the Lactococcus lactis cocci. While the sensitive strain cell-chains consist mainly of two cells, the NisI expressing cells display a length of up to 20 cells. Both results shed light on the immunity of lantibiotic producer strains, and their survival in high levels of their own lantibiotic in the habitat.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.